Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 13/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.45 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.44 |
| ▸ | SRC | P12931 | 3/20 | 0.44 |
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL592922 | 0.91 | DDR2 (0.50) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL593266 | 0.90 | GSK3A (0.47) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL593046 | 0.90 | GSK3A (0.55) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL10130556 | 0.90 | DDR2 (0.49) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL594764 | 0.90 | DDR2 (0.49) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL594192 | 0.90 | DDR2 (0.49) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL10157766 | 0.88 | DDR2 (0.47) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL10130548 | 0.88 | DDR2 (0.49) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL593396 | 0.87 | GSK3A (0.48) | GSK3ADDR2MAPK14SRCSYK | |
| SCHEMBL592879 | 0.86 | GSK3A (0.48) | GSK3ADDR2MAPK14SRCSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114873-B2 | 1,4-disubstituted naphthalenes as inhibitors of p38 map kinase | ARQULE, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | ARQULE, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311754-A1 | 1,4-Disubstituted Naphthalenes as Inhibitors of P38 Map Kinase | MAPK1, MAPK7, MAP3K1 | GSK3A 1443/4885DDR2 3028/4885MAPK14 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.